CLSA’s Brett Johnson provides analysis to The Mercury News on Senate Bill 17, legislation pending in Sacramento that will harm patient access to care and biotechnology innovation in California.
“Californians have legitimate concerns about access to affordable drugs, but SB 17 does not address them. It is a bad deal for business and does nothing to benefit patients.” – William J. Newell, CEO, Sutro Biopharma & Vice Chairman, California Life Sciences Association.
CLSA connects and strengthens the entire life sciences community across our great state.
CLSA’s Brett Johnson provides analysis to the LA Times on priority legislation in Sacramento for the life sciences sector.
CLSA’s Brett Johnson provides analysis to the San Francisco Business Times on three major bills (SB 790, SB 17 and AB 215) the life sciences sector is facing in Sacramento.
Did you miss it? CLSA is happy to share an overview of what we saw, who we talked to, and what we can expect leading up to BIO 2018 in Boston next June.
CLSA featured in The Los Angeles Times, reacting to the President’s 2018 Budget Request, and what it would mean for the life sciences industry.
CLSA was recently featured in BOSS Magazine regarding our efforts to drive solution-oriented public policies and advocacy activities that sustain and support life sciences research, investment and innovation in California. View the executive profile for more.
CLSA President & CEO Sara Radcliffe reacts to the President’s proposed $6 billion cut to the NIH’s budget in this San Diego Union-Tribune article.
CLSA’s Brett Johnson, Sr. Director of Policy & Regulatory Affairs, provides analysis and cites concerns regarding Assembly Bill 265, legislations introduced in the California state legislature that would ban drug companies from offering consumers coupons for drugs that have a lower cost alternative.
CLSA’s 2017 California Life Sciences Industry report featured in Bloomberg BNA regarding VC funding levels for the life sciences sector.
CLSA featured in a MassDevice article regarding the reintroduction of legislation to repeal the 2.3% medical device tax.
CLSA Pres. & CEO Sara Radcliffe was featured in GEN News, applauding the Congressional passage of the 21st Century Cures Act.
Did you miss the 2016 CLSA Pantheon Awards? Check out this article from the San Francisco Business Times.
CLSA’s 2017 California Life Sciences Industry Report featured in the San Diego Union-Tribune.
Via BioSpace, for a newly mortar-boarded PhD in the life sciences or a seasoned veteran of the pharma and biotech world, when searching for a new job, it’s a pretty basic notion to look for work where the jobs are.
Via The San Diego Union-Tribune: In a sign of growing interest in Los Angeles County as a major biomedical hub, the California Life Sciences Association has opened an office in Monrovia.
A new study conducted by the Orange County Business Council (OCBC) found that CLSA member Allergan’s California operations generated a combined annual economic activity in the state of approximately $6.35 billionand net economic impact of $3.45 billion. The economic impact is a direct result of the Company’s strong influence on employment in the state, generating more than 16,600 direct, indirect and induced jobs, with annual total statewide labor income of ~$1.55 billion.
From the House Energy & Commerce Committee: As this month of advocacy comes to a close, September is coming and every voice is needed on the #Path2Cures. Energy and Commerce Committee Chairman Fred Upton (R-MI) writes in an open letter to disease advocates, “Thanks to a remarkable outpouring and mobilization of rare disease advocates, August 2016 will go down in the books as the ‘Summer of Cures.’ … I am proud to report that we are closing in on the finish line.
CLSA Pres. & CEO Sara Radcliffe pens a letter to the editor of The Sacramento Bee responding to their Aug. 11 editorial endorsement of SB 1010, flawed legislation that could enable speculative buying of medicines, creating shortages and leading to growth in “gray markets” where medicine is sold to the highest bidder.
Featured in Life Science Network, Sara Radcliffe, president and CEO of the California Life Sciences Association, discusses some of the issues and obstacles facing the life sciences.
CLSA featured in The Associated Press regarding life sciences sector concerns with SB 1010.
The San Francisco Business Times publishes an article regarding the upcoming BIO 2016 Convention that includes reaction from CLSA’s Pres. & CEO Sara Radcliffe.
The launch of CLSA’s SB 1010 campaign was included in Politico’s Prescription Pulse health care news
San Francisco Business Times names CLSA Pres. & CEO Sara Radcliffe a “Most Influential Woman in Business”
GEN News tabulates a 2016 list of the top 10 U.S. biopharma clusters in the nation, relying on portions data from CLSA’s 2016 California Life Sciences Industry Report.
CLSA Pres. & CEO Sara Radcliffe chats with the San Diego Business Journal on the impact that the newly permanent R&D Tax Credit will have on life sciences organizations in San Diego and California.
A Letter to the Editor authored by CLSA President & CEO Sara Radcliffe was published in the Los Angeles Daily News. This letter responds to an opinion piece originally published February 18 by Heidi Sanborn, executive director of the California Product Stewardship Council, a key group pushing the local takeback initiatives in California.
In a Sacramento Bee op-ed, CLSA Pres. & CEO Sara Radcliffe warns California State Lawmakers to be wary of misguided proposals that claim to provide transparency, yet in reality only create hurdles to bringing drugs to market, slowing or reversing years of progress.
BioSpace provides an extended look into California’s top 4 life sciences clusters, relying on CLSA’s 2016 Life Sciences Industry Report.
CLSA Pres. & CEO Sara Radcliffe pens an op-ed in the San Diego Union-Tribune regarding the need to protect and nurture California’s life sciences innovation economy.
CLSA Pres. & CEO Sara Radcliffe chats with Michele Chandler of Investor’s Business Daily regarding the convergence of the healthcare and technology sectors.
Featured in the San Diego Business Journal, Sara Radcliffe, president and CEO of the California Life Sciences Association, discusses some of the issues and obstacles facing the life sciences.
CLSA featured in the San Diego Business Journal regarding San Diego’s vibrant research institutions, life sciences workforce and VC funding levels.
FierceMedicalDevices features CLSA in their article regarding the proposed delay of the medical device tax.
Bloomberg BNA provides coverage of CLSA’s 2016 California Life Sciences Industry Report.
Bloomberg provides coverage of CLSA’s Nov. 17, 2015 Reimbursement Decision Luncheon in San Francisco.
BioSpace provides coverage of CLSA’s 2016 California Life Sciences Industry Report.
GEN News provides coverage of CLSA’s 2016 California Life Sciences Industry Report.
Charles Piller of STAT (a Boston Globe publication) provides coverage of CLSA’s 2016 California Life Sciences Industry Report.
Ron Leuty of the San Francisco Business Times provides coverage of CLSA’s 2016 California Life Sciences Industry Report.
Chris Jennewein of the Times of San Diego provides coverage of CLSA’s 2016 California Life Sciences Industry Report.
CLSA President & CEO Sara Radcliffe comments on the establishment of the Congressional Life Science Caucus.
CLSA commends Reps. Scott Peters (D-CA) and Leonard Lance (R-NJ) on the creation of the Congressional Life Sciences Caucus, which will help strengthen the dialogue in Congress over the issues affecting the life sciences sector.
CLSA President & CEO Sara Radcliffe speaks with Luke Timmerman at the 14th Annual BIO Investors Forum in San Francisco regarding CLSA’s mission, the value of medical innovation, preparation for BIO 2016 and more.
CLSA Pres. & CEO Sara Radcliffe speaks with The BIO Report to discuss some of the key policy issues facing the biotechnology innovation ecosystem. This podcast covers a variety of public policy issues, including PDUFA VI, Trans Pacific Partnership (TPP) and the 21st Century Cures Act.
CLSA Pres. & CEO Sara Radcliffe sits down with CNBC to discuss the disastrous affects that government-imposed pricing controls on drugs would have on biomedical innovation in California.
CLSA Pres. & CEO Sara Radcliffe recently sat down with mendelspod.com to discuss the value of medical innovation in California.
Sara Radcliffe, president and CEO of the California Life Sciences Association, discusses the so-called “California Drug Price Relief Act” with the San Francisco Business Times.
Ahead of the AdvaMed conference (Oct. 5-7, 2015) in San Diego and the BIO Investor Forum in San Francisco (Oct. 12-16), Big3Bio has a two-part Q&A series with new California Life Sciences Association (CLSA) President and CEO Sara Radcliffe.
Via Legal Newsline, two groups representing California’s life sciences sector say they are disappointed with recent remarks by U.S. Rep. Darrell Issa about a House-introduced patent reform bill.
Carol Cox, a member of the California Life Sciences Association (CLSA) board of directors and executive vice president of NuVasive, pens an op-ed in the San Diego Business Journal on the medical technology revolution taking place in Southern California.
CLSA Pres. & CEO Sara Radcliffe discusses the AdvaMed 2015 with the San Diego Business Journal.
Via the Times of San Diego, Two influential biotech-industry trade groups said Monday they are disappointed with recent remarks by Rep. Darrell Issa criticizing the industry’s role in the debate on patent reform.
CLSA President & CEO Sara Radcliffe pens an op-ed in The Sacramento Bee regarding H.R. 9, federal legislation that would weaken the process that turns research into products, new companies.
Paul Hastings, CLSA Board Member and OncoMed Pharmaceuticals Chairman & CEO, pens an op-ed in the San Francisco Business Times calling on Congress to safeguard and preserve our patent system. Failure to do so would be be a blow to our role as the world’s leader in life sciences innovation.
CLSA President & CEO Sara Radcliffe discusses California’s leadership in life sciences in this San Diego Union-Tribune article.
CLSA’s President & CEO Sara Radliffe & CLSI Executive Director Lori Lindburg chat with Ron Leuty of the San Francisco Business Times regarding San Francisco’s preparation to host BIO 2016.
CLSA featured in San Diego Business Journal article on the need to increase H1-B Visa’s to foster a greater ability for life sciences to compete globally.
BioSpace.com article on CLSA discusses the merger of CHI & BayBio, making California Life Sciences Association the Largest Life Sciences Advocacy Group in U.S.
The Wall Street Journal called for the Supreme Court to strike down Alameda County’s drug take back proposal.
CLSA is featured in a GEN News article applauding funding increases for the NIH as part of the 21st Century Cures Act Initiative.
Todd Gillenwater, CLSA’s Executive Vice President – Advocacy & External Relations, pens an op-ed in The Hill calling on Congress to protect FDA user fees from sequestration.
Newt Gingrich: Double the N.I.H. Budget NY Times By Newt Gingrich APRIL 22, 2015 MCLEAN, Va. — NO one who lived through the 1990s would have suspected that one day people would look back on the period as a golden age of bipartisan cooperation. But in some important ways, it was. Amid the policy fights that … Continue reading NY Times: Opinion: Double the N.I.H. Budget
$3M California Initiative to Advance Precision Medicine From Big3Bio San Diego April 15, 2015 Coverage of The California Initiative to Advance Precision Medicine (aka the “Google maps for health”): Silicon Valley Business Journal: “By weaving together a hodgepodge of patient and clinical data, other important factors and scientific know-how, California officials hope to create a sort … Continue reading Big3Bio: $3M California Initiative to Advance Precision Medicine
The Reality of Prescription Drug Spending in Medicaid From our partners at PhRMA By Robert Zirkelbach April 9, 2015 Recent rhetoric on spending in state Medicaid programs often overstates the cost impact of prescription medicines and ignores the competitive biopharmaceutical market that exists in the U.S., which can generate significant savings for Medicaid programs. Prescription … Continue reading The Reality of Prescription Drug Spending in Medicaid
The top companies in med tech: 2014 revenue results By Stacy Lawrence & Varun Saxena, FierceMedicalDevices April 6, 2015 Big med tech companies come in three types: med tech pure-plays; major conglomerates that include non-healthcare businesses; and mixed drug/device players. All three of these groups have been making big moves to transform themselves this year. … Continue reading FierceMedicalDevices: The top companies in med tech: 2014 revenue results